Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease.

Autor: Steenholdt C; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Lorentsen RD; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Petersen PN; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Widigson ES; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität, Berlin, Germany.; Graduate Research Training Program PharMetrX, Berlin, Germany., Kloft C; Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universität, Berlin, Germany., Klaasen RA; Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway., Brynskov J; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark.

Publikováno v: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2024 Jun; Vol. 39 (6), pp. 1088-1098. Date of Electronic Publication: 2024 Feb 21.

Trajectories of health-related quality of life and fatigue during vedolizumab therapy in inflammatory bowel disease.

Autor: Steenholdt C; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Lorentsen RD; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Petersen PN; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark., Brynskov J; Department of Gastroenterology, Herlev and Gentofte Hospital, Herlev, Denmark.

Publikováno v: Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2023 Apr; Vol. 38 (4), pp. 574-583. Date of Electronic Publication: 2023 Jan 06.